Can-Fite BioPharma (CANF) Competitors $0.66 -0.01 (-1.64%) Closing price 08/15/2025 03:47 PM EasternExtended Trading$0.67 +0.01 (+0.76%) As of 08/15/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CANF vs. ACXP, DWTX, XFOR, APRE, SNGX, SONN, CHRO, ADXN, CLRB, and CYCNShould you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include Acurx Pharmaceuticals (ACXP), Dogwood Therapeutics (DWTX), X4 Pharmaceuticals (XFOR), Aprea Therapeutics (APRE), Soligenix (SNGX), Sonnet BioTherapeutics (SONN), Chromocell Therapeutics (CHRO), Addex Therapeutics (ADXN), Cellectar Biosciences (CLRB), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry. Can-Fite BioPharma vs. Its Competitors Acurx Pharmaceuticals Dogwood Therapeutics X4 Pharmaceuticals Aprea Therapeutics Soligenix Sonnet BioTherapeutics Chromocell Therapeutics Addex Therapeutics Cellectar Biosciences Cyclerion Therapeutics Acurx Pharmaceuticals (NASDAQ:ACXP) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends. Is ACXP or CANF more profitable? Can-Fite BioPharma's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -436.83% -192.25% Can-Fite BioPharma N/A N/A N/A Do insiders and institutionals have more ownership in ACXP or CANF? 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, ACXP or CANF? Acurx Pharmaceuticals has a beta of -1.27, suggesting that its stock price is 227% less volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Which has better earnings and valuation, ACXP or CANF? Can-Fite BioPharma has higher revenue and earnings than Acurx Pharmaceuticals. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$14.10M-$10.69-0.48Can-Fite BioPharma$674K3.47-$7.63M-$1.79-0.37 Does the media prefer ACXP or CANF? In the previous week, Acurx Pharmaceuticals had 15 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 16 mentions for Acurx Pharmaceuticals and 1 mentions for Can-Fite BioPharma. Acurx Pharmaceuticals' average media sentiment score of 0.81 beat Can-Fite BioPharma's score of -1.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Acurx Pharmaceuticals Positive Can-Fite BioPharma Negative Do analysts recommend ACXP or CANF? Acurx Pharmaceuticals presently has a consensus price target of $31.00, suggesting a potential upside of 506.65%. Can-Fite BioPharma has a consensus price target of $14.00, suggesting a potential upside of 2,018.00%. Given Can-Fite BioPharma's higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than Acurx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCan-Fite BioPharma beats Acurx Pharmaceuticals on 10 of the 13 factors compared between the two stocks. Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CANF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CANF vs. The Competition Export to ExcelMetricCan-Fite BioPharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$2.34M$778.25M$5.75B$20.97BDividend YieldN/A4.84%3.91%3.60%P/E Ratio-0.371.1831.1127.94Price / Sales3.4725.64434.8354.16Price / CashN/A19.5636.7823.73Price / Book0.386.599.085.26Net Income-$7.63M-$4.67M$3.26B$994.11M7 Day Performance-3.80%3.22%7.36%1.80%1 Month Performance-36.75%2.46%5.47%1.74%1 Year Performance-74.28%13.65%30.61%13.36% Can-Fite BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CANFCan-Fite BioPharma1.9677 of 5 stars$0.66-1.6%$14.00+2,018.0%-73.9%$2.34M$674K-0.378Negative NewsShort Interest ↑ACXPAcurx Pharmaceuticals3.0289 of 5 stars$0.29-4.8%$8.00+2,636.0%-87.5%$9.44MN/A-0.423News CoverageEarnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionDWTXDogwood Therapeutics1.6079 of 5 stars$4.86+0.2%$10.00+105.8%N/A$9.27MN/A-0.275News CoverageEarnings ReportXFORX4 Pharmaceuticals4.3415 of 5 stars$1.58-1.3%$72.33+4,478.1%-85.0%$9.26M$2.56M0.7480News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionGap DownAPREAprea Therapeutics3.5762 of 5 stars$1.70+2.4%$15.50+811.8%-50.4%$9.18M$1.50M-0.727Earnings ReportAnalyst RevisionSNGXSoligenix1.9003 of 5 stars$3.11+13.5%$6.00+92.9%-16.8%$8.94M$120K-0.7220News CoverageEarnings ReportAnalyst DowngradeGap UpHigh Trading VolumeSONNSonnet BioTherapeutics2.9144 of 5 stars$2.81flat$20.00+611.7%-45.4%$8.90M$20K0.0010Earnings ReportAnalyst UpgradeGap DownCHROChromocell TherapeuticsN/A$1.34+6.3%N/A-83.4%$8.69MN/A-1.084Gap UpHigh Trading VolumeADXNAddex Therapeutics2.7391 of 5 stars$8.24+1.7%$30.00+264.3%+1.8%$8.58M$460K-24.2230Positive NewsGap UpCLRBCellectar Biosciences2.7636 of 5 stars$5.06+7.2%$375.00+7,311.1%-92.9%$8.54MN/A-0.2310News CoverageEarnings ReportAnalyst ForecastShort Interest ↑CYCNCyclerion Therapeutics2.7364 of 5 stars$2.79+7.5%N/A-14.5%$8.33M$2M-2.4030Short Interest ↓ Related Companies and Tools Related Companies Acurx Pharmaceuticals Alternatives Dogwood Therapeutics Alternatives X4 Pharmaceuticals Alternatives Aprea Therapeutics Alternatives Soligenix Alternatives Sonnet BioTherapeutics Alternatives Chromocell Therapeutics Alternatives Addex Therapeutics Alternatives Cellectar Biosciences Alternatives Cyclerion Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CANF) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredAmericans are rushing into gold (but not billionaires!)Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access